» Articles » PMID: 16870268

Immunomodulatory Effects of 3-hydroxy-3-methylglutaryl Coenzyme-A Reductase Inhibitors, Potential Therapy for Relapsing Remitting Multiple Sclerosis

Overview
Journal J Neuroimmunol
Specialty Neurology
Date 2006 Jul 28
PMID 16870268
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

This study characterized immunomodulatory targets of statins in humans and their potential for treatment of relapsing remitting multiple sclerosis (RR MS). Statins inhibited the proliferative response of mononuclear cells. Simvastatin, the statin with the strongest antiproliferative effect, inhibited IFN-gamma-induced expression of MHC class II DR on monocytes and decreased their antigen presenting capacity. As for T lymphocytes, it inhibited their activation and expression of the Th1 lineage differentiation markers. Simvastatin inhibited IFN-gamma, TNF-alpha, and IL-2 secretion, as well as the expression of T-bet, a transcription factor that regulates Th1 cell differentiation.

Citing Articles

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.

Blackstone J, Williams T, Nicholas J, Bordea E, De Angelis F, Bianchi A BMJ Open. 2024; 14(9):e086414.

PMID: 39284697 PMC: 11409264. DOI: 10.1136/bmjopen-2024-086414.


Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.

Huntemann N, Rolfes L, Pawlitzki M, Ruck T, Pfeuffer S, Wiendl H Drugs. 2021; 81(9):1031-1063.

PMID: 34086251 PMC: 8217012. DOI: 10.1007/s40265-021-01526-w.


Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?.

Vasileiadis G, Dardiotis E, Mavropoulos A, Tsouris Z, Tsimourtou V, Bogdanos D Auto Immun Highlights. 2018; 9(1):9.

PMID: 30415321 PMC: 6230324. DOI: 10.1007/s13317-018-0109-x.


Statin treatment in multiple sclerosis: a systematic review and meta-analysis.

Pihl-Jensen G, Tsakiri A, Frederiksen J CNS Drugs. 2015; 29(4):277-91.

PMID: 25795002 DOI: 10.1007/s40263-015-0239-x.


Statins increase the frequency of circulating CD4+ FOXP3+ regulatory T cells in healthy individuals.

Rodriguez-Perea A, Montoya C, Olek S, Chougnet C, Velilla P J Immunol Res. 2015; 2015:762506.

PMID: 25759848 PMC: 4352479. DOI: 10.1155/2015/762506.